David P. Meeker, M.D. is the CEO and Chairman of Rhythm Pharmaceuticals, Inc., a company focused on developing treatments for rare genetic diseases tied to obesity. With an M.D. from the University of Vermont and an Advanced Management Program completion...

David P. Meeker, M.D. is the CEO and Chairman of Rhythm Pharmaceuticals, Inc., a company focused on developing treatments for rare genetic diseases tied to obesity. With an M.D. from the University of Vermont and an Advanced Management Program completion at Harvard Business School, Dr. Meeker brings a strong background in medicine and leadership to the role. He has over 25 years of experience in the biotech and pharmaceutical sectors, having served as the former CEO of Genzyme, overseeing key developments in rare diseases and multiple sclerosis treatments. He has been part of the Rhythm team since July 2023 and has also held various high-level positions within large pharmaceutical companies. Under his leadership, the company is dedicated to creating valuable therapies, reflecting both innovation and a deep understanding of patient needs. Dr. Meeker's practical approach integrates medical knowledge with business strategy, driving significant growth and advancements in how we treat obesity-related health issues.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Rhythm Pharmaceuticals, Inc. CEOs

R

David P. Meeker, M.D.

CEO of Rhythm Pharmaceuticals, Inc.

Education

M.D. from a recognized institution.

Field of Expertise

Healthcare & Life Sciences - Medicine

Sector of Economy

Healthcare

Born

January 1, 1978 - 47 years ago

CEO of Rhythm Pharmaceuticals, Inc. for

1 year 10 months (Jul 2023 - Present)

Previous Experience

Various leadership roles in the biopharmaceutical industry.

Rivals

Competitors/colleagues of David P. Meeker, M.D.

Holdings

See how much did David P. Meeker, M.D. make over time.

Dr. David P. Meeker’s holdings primarily consist of Rhythm Pharmaceuticals common stock (RYTM). When he joined Rhythm in July 2023, his net worth was significantly tied to this asset. As the company continues to focus on innovative treatments for rare...

Dr. David P. Meeker’s holdings primarily consist of Rhythm Pharmaceuticals common stock (RYTM). When he joined Rhythm in July 2023, his net worth was significantly tied to this asset. As the company continues to focus on innovative treatments for rare genetic disorders, fluctuations in RYTM's stock value directly impact his wealth. While exact values can vary, tracking how this plays out over time can reveal insights into both his investment strategies and confidence in the company’s direction. As he works to advance the goals of Rhythm Pharmaceuticals, the evolution of his holdings will likely be under close scrutiny, reflecting his commitment to the company's long-term success.

Mar 18, 2025

R

shares

RYTM @ $52.29

Total Stock Sold

$2.81M

RYTM

$2.81M

64,029 RYTM shares

What if they kept their stock?

If David P. Meeker, M.D. didn't sell their stock, today they would have:
Extra RYTM64,029 shares worth $1.21M.
This is -56.88% and $1.60M less than what they got when they sold the stock.

Insider Trading

See recent insider trades of David P. Meeker, M.D..

RYTM

$566.25K

RYTM at $57.22/share

Feb 14, 2025

Sale

RYTM

$254.24K

RYTM at $59.43/share

Feb 1, 2025

Sale

RYTM

$1.78M

RYTM at $39.22/share

Mar 19, 2024

Sale

RYTM

99,000 shares

RYTM

Feb 16, 2024

Received

RYTM

$196.51K

RYTM at $45.06/share

Feb 1, 2024

Sale

RYTM

$201.71K

RYTM at $20.17/share

Mar 30, 2021

Purchase

RYTM

$425.00K

RYTM at $17.00/share

Oct 10, 2017

Purchase

Compensation History

See how much did David P. Meeker, M.D. make over time.

In 2023, Dr. Meeker received total compensation amounting to approximately $7.2 million. This includes a base salary of $704,715, along with a bonus of $634,053, which reflects strong performance in achieving corporate goals. Interestingly, there were no stock grants or options vested for him this year, meaning most of his compensation was cash-based. The compensation plan is designed to align executive interests with those of shareholders, emphasizing performance metrics tied directly to the company's market growth and product development. This structure suggests that Dr. Meeker is incentivized to push for success and make impactful decisions that benefit not just the company but also the shareholders.

Year

2023

Total Compensation

$1.35M

Salary

$704.72K

Board Justification

The compensation philosophy is designed to attract, retain, and motivate executives while aligning their interests with those of shareholders, with a significant portion of compensation tied to performance metrics.

Bonus

$634.05K

Board Justification

The actual bonus payout for 2023 was determined based on the achievement of corporate goals at 130% of target, reflecting significant progress on key objectives made during the year.

Other

$11.89K

Board Justification

This amount includes employer matching contributions to the 401(k) plan.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was reported as vested in 2023; only stock grants and options are included in the total compensation calculations.

Performance Metrics

The performance metrics for 2023 included corporate goals related to commercial growth and product development.

Other Rhythm Pharmaceuticals, Inc. CEOs

Here are other CEOs of Rhythm Pharmaceuticals, Inc.

Keith Gottesdiener, M.D.

Ex-CEO of Rhythm Pharmaceuticals, Inc.

January 2018 - January 2020